5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.
>>>
pixel

LIXT Insider Trading

Insider Ownership Percentage: 29.20%
Insider Buying (Last 12 Months): $34,161.00
Insider Selling (Last 12 Months): $0.00

Lixte Biotechnology Insider Trading History Chart

This chart shows the insider buying and selling history at Lixte Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lixte Biotechnology Share Price & Price History

Current Price: $0.68
Price Change: Price Decrease of -0.02 (-2.86%)
As of 12/8/2022 01:00 AM ET

This chart shows the closing price history over time for LIXT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Lixte Biotechnology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2022Eric FormanCOOBuy1,457$0.56$815.9299,599View SEC Filing Icon  
11/21/2022Regina BrownDirectorBuy5,000$0.58$2,900.006,300View SEC Filing Icon  
11/17/2022Eric FormanCOOBuy4,852$0.54$2,620.0881,935View SEC Filing Icon  
11/14/2022Rene BernardsDirectorBuy52,500$0.53$27,825.00125,000View SEC Filing Icon  
See Full Table
5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.
>>>
pixel

SEC Filings (Institutional Ownership Changes) for Lixte Biotechnology (NASDAQ:LIXT)

5.25% of Lixte Biotechnology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LIXT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Lixte Biotechnology Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/14/2022Renaissance Technologies LLC90,664$51K0.0%+58.5%0.545%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC57,189$43K0.0%N/A0.344%Search for SEC Filing on Google Icon
8/12/2022Almanack Investment Partners LLC.248,084$0.19M0.0%-66.7%1.490%Search for SEC Filing on Google Icon
5/20/2022EP Wealth Advisors LLC25,025$31K0.0%N/A0.150%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.13,425$28K0.0%+191.9%0.098%Search for SEC Filing on Google Icon
11/4/2021Almanack Investment Partners LLC.806,050$1.68M0.1%-17.9%5.863%Search for SEC Filing on Google Icon
8/16/2021State Street Corp33,600$0.10M0.0%N/A0.244%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC65,511$0.20M0.0%-17.8%0.477%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC50,900$0.15M0.0%N/A0.370%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.74,383$0.23M0.0%N/A0.544%Search for SEC Filing on Google Icon
8/4/2021Almanack Investment Partners LLC.982,046$2.98M0.3%-5.8%7.189%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC23,813$79K0.0%N/A0.174%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC23,813$79K0.0%N/A0.174%Search for SEC Filing on Google Icon
5/11/2021Almanack Investment Partners LLC.1,042,105$3.43M0.3%N/A7.698%Search for SEC Filing on Google Icon
2/16/2021Santa Monica Partners LP166,667$0.53M0.4%N/A1.347%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Lixte Biotechnology logo
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Read More on Lixte Biotechnology

Today's Range

Now: $0.68
Low: $0.67
High: $0.71

50 Day Range

MA: $0.57
Low: $0.48
High: $0.77

52 Week Range

Now: $0.68
Low: $0.43
High: $4.95

Volume

4,539 shs

Average Volume

38,110 shs

Market Capitalization

$11.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Lixte Biotechnology?

Lixte Biotechnology's top insider investors include:
  1. Rene Bernards (Director)
  2. Eric Forman (COO)
  3. Regina Brown (Director)
Learn More about top insider investors at Lixte Biotechnology.

Who are the major institutional investors of Lixte Biotechnology?

Lixte Biotechnology's top institutional investors include:
  1. Renaissance Technologies LLC — 0.54%
Learn More about top institutional investors of Lixte Biotechnology stock.

Which major investors are buying Lixte Biotechnology stock?

In the last quarter, LIXT stock was purchased by institutional investors including:
  1. Renaissance Technologies LLC
Within the previous year, these company insiders have bought Lixte Biotechnology stock:
  1. Rene Bernards (Director)
  2. Eric Forman (COO)
  3. Regina Brown (Director)
Learn More investors buying Lixte Biotechnology stock.
Bear Market… Bull Market… Who Cares?
Many investors can do well in bull markets but then lose a large percentage of their portfolio during a bear market…

All because they don’t know where to invest.

Our experts say these 4 stocks are positioned well - even in a down market.
>>> Click Here.
pixel